A Phase 2 interventional study of IDP-126 Gel and IDP-126 Component A in Acne Vulgaris, sponsored by Bausch Health Americas, Inc.. Completed at 34 sites in 2 countries. Open to participants aged 9 Years to 99 Years. Per ClinicalTrials.gov, last updated 2021-11-10.
Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Acne Vulgaris by Bausch Health Companies Inc. — 1 open to participants now, 1 under way, none of them phase 3. Acne Vulgaris · Bausch Health Companies Inc..
Among the 36 studies in Acne Vulgaris by Bausch Health Companies Inc., this one is the 9th largest by enrollment of the 35 interventional ones that give a count, is one of 3 that started in 2017, is one of 10 in phase 2, and was the 28th registered.
791 studies on the registry are indexed under Acne Vulgaris; 94 are open to participants now.
Browse Acne Vulgaris studies →1 of the 36 studies in Acne Vulgaris by Bausch Health Companies Inc. is open now, in 1 country. Recruiting first, the newest first:
Bausch Health Americas, Inc. · Sites in United States
Ages 9–11
By country, each count listing its studies:
Of the 47 Acne Vulgaris studies recruiting now, 17 (36%) set no upper age limit and 29 (62%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 9 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 741 is above the median of 70 across 673 interventional studies indexed under Acne Vulgaris.
Median enrollment 247 across the 35 interventional studies, 200 across the 1 observational. Of the 31 that completed or were terminated, 19 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Bausch Health Americas, Inc., one of the names counted as Bausch Health Companies Inc.. Under that name alone:
Bausch Health Americas, Inc. is the lead sponsor of 213 studies on the registry; 7 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 18 (72%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 36 studies in Acne Vulgaris by Bausch Health Companies Inc., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group, Clinical Study in the Treatment of Acne Vulgaris
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group, Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Gel
Drug: IDP-126 Gel
Component A
Drug: IDP-126 Component A
Component B
Drug: IDP-126 Component B
Component C
Drug: IDP-126 Component C
Vehicle Gel
Drug: IDP-126 Vehicle Gel
Gel
Component A
Component B
Component C
Vehicle Gel
Inflammatory Lesion Counts
Absolute change from Baseline to Week 12 in mean inflammatory lesion counts
Time frame: Baseline to Week 12
Non-inflammatory Lesion Counts
Absolute change from Baseline to Week 12 in mean non-inflammatory lesion counts
Time frame: Baseline to Week 12
Percentage of Participants With Success on the Evaluator's Global Severity Score
Success was defined as at least a two grade reduction and clear or almost clear at Week 12. The Evaluator's Global Severity Score has grades for acne severity of 0 (Clear), 1 (Almost Clear), 2 (Mild), 3 (Moderate), and 4 (Severe), with higher scores indicating worse severity.
Time frame: Baseline to Week 12
Inflammatory Lesion Count Changes at Week 2, 4, and 8
Absolute change from Baseline to Week 2, 4, and 8 in mean inflammatory lesion counts
Time frame: Baseline to Week 2, 4, 8
Non-inflammatory Lesion Count Changes at Week 2, 4, and 8
Absolute change from Baseline to Week 2, 4, and 8 in mean non-inflammatory lesion counts
Time frame: Baseline to Week 2, 4, 8
Inflammatory Lesion Count Percentage Changes at Week 2, 4, and 8
Percentage change from Baseline to Week 2, 4, and 8 in mean inflammatory lesion counts
Time frame: Baseline to Week 2, 4, 8
Non-inflammatory Lesion Count Percentage Changes at Week 2, 4, and 8
Percentage change from Baseline to Week 2, 4, and 8 in mean non-inflammatory lesion counts
Time frame: Baseline to Week 2, 4, 8
Percentage of Participants With Success on the Evaluator's Global Severity Score at Weeks 2, 4, and 8
Success was defined as at least a two grade reduction and clear or almost clear at the visit. The Evaluator's Global Severity Score has grades for acne severity of 0 (Clear), 1 (Almost Clear), 2 (Mild), 3 (Moderate), and 4 (Severe), with higher scores indicating worse severity.
Time frame: Baseline to Week 2, 4, and 8
Percentage of Participants With Two Grade Success on the Evaluator's Global Severity Score - at Weeks 2, 4, and 8
Two grade success was defined as at least a two grade reduction. The Evaluator's Global Severity Score has grades for acne severity of 0 (Clear), 1 (Almost Clear), 2 (Mild), 3 (Moderate), and 4 (Severe), with higher scores indicating worse severity.
Time frame: Baseline to Week 2, 4, and 8
| Milestone | IDP-126 Gel | IDP-126 Component A | IDP-126 Component B | IDP-126 Component C | IDP-126 Vehicle Gel |
|---|---|---|---|---|---|
| Started | 147 | 150 | 146 | 150 | 148 |
| Completed | 125 | 132 | 133 | 132 | 127 |
| Not completed | 22 | 18 | 13 | 18 | 21 |
Absolute change from Baseline to Week 12 in mean inflammatory lesion counts
| lesions | IDP-126 Gel | IDP-126 Component A | IDP-126 Component B | IDP-126 Component C | IDP-126 Vehicle Gel |
|---|---|---|---|---|---|
| Inflammatory Lesion Counts | -29.9 ± 11.86 | -26.7 ± 11.74 | -24.8 ± 11.71 | -26.8 ± 11.69 | -19.6 ± 12.12 |
Absolute change from Baseline to Week 12 in mean non-inflammatory lesion counts
| lesions | IDP-126 Gel | IDP-126 Component A | IDP-126 Component B | IDP-126 Component C | IDP-126 Vehicle Gel |
|---|---|---|---|---|---|
| Non-inflammatory Lesion Counts | -35.5 ± 16.25 | -29.9 ± 16.40 | -27.8 ± 15.97 | -30.0 ± 16.40 | -21.8 ± 16.58 |
Success was defined as at least a two grade reduction and clear or almost clear at Week 12. The Evaluator's Global Severity Score has grades for acne severity of 0 (Clear), 1 (Almost Clear), 2 (Mild), 3 (Moderate), and 4 (Severe), with higher scores indicating worse severity.
| percentage of participants | IDP-126 Gel | IDP-126 Component A | IDP-126 Component B | IDP-126 Component C | IDP-126 Vehicle Gel |
|---|---|---|---|---|---|
| Percentage of Participants With Success on the Evaluator's Global Severity Score | 52.5 | 27.8 | 30.5 | 30.3 | 8.1 |
Absolute change from Baseline to Week 2, 4, and 8 in mean inflammatory lesion counts
| lesions | IDP-126 Gel | IDP-126 Component A | IDP-126 Component B | IDP-126 Component C | IDP-126 Vehicle Gel |
|---|---|---|---|---|---|
| Week 2 | -14.0 ± 11.62 | -11.8 ± 10.80 | -13.8 ± 10.50 | -13.4 ± 10.76 | -9.2 ± 9.58 |
| Week 4 | -21.0 ± 10.33 | -17.1 ± 12.07 | -18.8 ± 12.05 | -17.7 ± 11.49 | -14.8 ± 10.26 |
| Week 8 | -25.8 ± 11.97 | -23.0 ± 11.69 | -23.1 ± 13.95 | -22.8 ± 9.86 | -17.5 ± 10.86 |
Absolute change from Baseline to Week 2, 4, and 8 in mean non-inflammatory lesion counts
| lesions | IDP-126 Gel | IDP-126 Component A | IDP-126 Component B | IDP-126 Component C | IDP-126 Vehicle Gel |
|---|---|---|---|---|---|
| Week 2 | -12.9 ± 12.90 | -11.0 ± 14.31 | -11.2 ± 10.97 | -11.3 ± 14.02 | -9.2 ± 11.94 |
| Week 4 | -21.4 ± 14.33 | -18.6 ± 13.74 | -15.8 ± 13.77 | -18.0 ± 14.35 | -13.7 ± 11.78 |
| Week 8 | -30.5 ± 15.95 | -25.1 ± 15.43 | -21.7 ± 16.08 | -26.8 ± 14.68 | -17.6 ± 15.29 |
Percentage change from Baseline to Week 2, 4, and 8 in mean inflammatory lesion counts
| percentage change | IDP-126 Gel | IDP-126 Component A | IDP-126 Component B | IDP-126 Component C | IDP-126 Vehicle Gel |
|---|---|---|---|---|---|
| Week 2 | -35.89 ± 29.073 | -30.27 ± 26.417 | -35.10 ± 26.442 | -35.23 ± 26.926 | -24.18 ± 26.000 |
| Week 4 | -54.42 ± 22.683 | -44.37 ± 28.511 | -47.55 ± 28.040 | -46.32 ± 27.664 | -39.95 ± 27.304 |
| Week 8 | -66.07 ± 22.239 | -59.07 ± 25.573 | -59.55 ± 31.990 | -60.10 ± 23.863 | -46.61 ± 27.495 |
Percentage change from Baseline to Week 2, 4, and 8 in mean non-inflammatory lesion counts
| percentage change | IDP-126 Gel | IDP-126 Component A | IDP-126 Component B | IDP-126 Component C | IDP-126 Vehicle Gel |
|---|---|---|---|---|---|
| Week 2 | -27.07 ± 26.440 | -23.39 ± 30.433 | -23.72 ± 22.845 | -24.91 ± 28.698 | -19.68 ± 23.194 |
| Week 4 | -43.17 ± 27.162 | -39.28 ± 26.422 | -33.84 ± 29.592 | -38.14 ± 27.765 | -29.53 ± 26.025 |
| Week 8 | -60.05 ± 25.164 | -52.76 ± 27.916 | -47.29 ± 32.982 | -54.17 ± 26.530 | -37.84 ± 29.933 |
Success was defined as at least a two grade reduction and clear or almost clear at the visit. The Evaluator's Global Severity Score has grades for acne severity of 0 (Clear), 1 (Almost Clear), 2 (Mild), 3 (Moderate), and 4 (Severe), with higher scores indicating worse severity.
| percentage of participants | IDP-126 Gel | IDP-126 Component A | IDP-126 Component B | IDP-126 Component C | IDP-126 Vehicle Gel |
|---|---|---|---|---|---|
| Week 2 | 1.49 | 1.35 | 0.71 | 2.68 | 0.00 |
| Week 4 | 8.17 | 6.77 | 2.79 | 4.27 | 1.36 |
| Week 8 | 20.46 | 15.97 | 15.26 | 15.75 | 3.51 |
Two grade success was defined as at least a two grade reduction. The Evaluator's Global Severity Score has grades for acne severity of 0 (Clear), 1 (Almost Clear), 2 (Mild), 3 (Moderate), and 4 (Severe), with higher scores indicating worse severity.
| percentage of participants | IDP-126 Gel | IDP-126 Component A | IDP-126 Component B | IDP-126 Component C | IDP-126 Vehicle Gel |
|---|---|---|---|---|---|
| Week 2 | 2.95 | 2.78 | 1.45 | 5.44 | 1.36 |
| Week 4 | 11.46 | 10.53 | 5.83 | 8.51 | 2.12 |
| Week 8 | 28.74 | 22.79 | 19.97 | 20.66 | 4.43 |
Collected over 12 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IDP-126 Gel | 0/141 (0%) | 1/141 (0.7%) | 30/141 (21.3%) |
| IDP-126 Component A | 0/146 (0%) | 0/146 (0%) | 29/146 (19.9%) |
| IDP-126 Component B | 0/144 (0%) | 0/144 (0%) | 6/144 (4.2%) |
| IDP-126 Component C | 0/148 (0%) | 3/148 (2%) | 19/148 (12.8%) |
| IDP-126 Vehicle Gel | 0/146 (0%) | 0/146 (0%) | 7/146 (4.8%) |
| Event | IDP-126 Gel | IDP-126 Component A | IDP-126 Component B | IDP-126 Component C | IDP-126 Vehicle Gel |
|---|---|---|---|---|---|
| Sickle cell anemia with crisisBlood and lymphatic system disorders | 1/141 | 0/146 | 0/144 | 0/148 | 0/146 |
| EnteritisGastrointestinal disorders | 0/141 | 0/146 | 0/144 | 1/148 | 0/146 |
| HyperbilirubinemiaHepatobiliary disorders | 0/141 | 0/146 | 0/144 | 1/148 | 0/146 |
| Abortion inducedSurgical and medical procedures | 0/141 | 0/146 | 0/144 | 1/148 | 0/146 |
| Event | IDP-126 Gel | IDP-126 Component A | IDP-126 Component B | IDP-126 Component C | IDP-126 Vehicle Gel |
|---|---|---|---|---|---|
| Application Site PainGeneral disorders | 11/141 | 16/146 | 1/144 | 5/148 | 1/146 |
| Viral Upper Respiratory Tract InfectionInfections and infestations | 10/141 | 5/146 | 3/144 | 5/148 | 5/146 |
| Application Site DrynessGeneral disorders | 9/141 | 8/146 | 2/144 | 9/148 | 1/146 |
One participant in the IDP-126 Gel group did not receive study medication and thus is not included in the demography population.
| Age, Continuous(years) | IDP-126 Gel | IDP-126 Component A | IDP-126 Component B | IDP-126 Component C | IDP-126 Vehicle Gel | Total |
|---|---|---|---|---|---|---|
| Median | 17 (11 to 46) | 17 (10 to 60) | 17 (10 to 45) | 17 (11 to 50) | 17 (11 to 47) | 17 (10 to 60) |
| Sex: Female, Male(Participants) | IDP-126 Gel | IDP-126 Component A | IDP-126 Component B | IDP-126 Component C | IDP-126 Vehicle Gel | Total |
|---|---|---|---|---|---|---|
| Female | 94 | 86 | 91 | 93 | 89 | 453 |
| Male | 52 | 64 | 55 | 57 | 59 | 287 |
| Race (NIH/OMB)(Participants) | IDP-126 Gel | IDP-126 Component A | IDP-126 Component B | IDP-126 Component C | IDP-126 Vehicle Gel | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 1 | 1 | 2 | 6 |
| Asian | 10 | 6 | 8 | 9 | 17 | 50 |
| Native Hawaiian or Other Pacific Islander | 2 | 4 | 0 | 1 | 0 | 7 |
| Black or African American | 24 | 26 | 30 | 20 | 26 | 126 |
| White | 98 | 109 | 101 | 109 | 95 | 512 |
| More than one race | 11 | 4 | 6 | 10 | 8 | 39 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Baseline Evaluator's Global Severity Score(Participants) | IDP-126 Gel | IDP-126 Component A | IDP-126 Component B | IDP-126 Component C | IDP-126 Vehicle Gel | Total |
|---|---|---|---|---|---|---|
| Moderate | 124 | 119 | 124 | 129 | 127 | 623 |
| Severe | 22 | 31 | 22 | 21 | 21 | 117 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Ran from Oct 2017 to primary completion in Apr 2019, 18 months.
Results were first posted in Nov 2021, 2 years 6 months after primary completion. A results delay was requested in Oct 2019.
Of 29 industry-sponsored phase 2 interventional studies under Acne Vulgaris, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 18 months is above that.
Counting every sponsor, half of 37 studies reached it within 9 months; a quarter within 6 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: IDP-126
Bausch Health Americas, Inc. →